Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15916667 | 0.80 | ANPEP (0.40) | ANPEPLAP3 | |
| SCHEMBL5199147 | 0.77 | ANPEP (0.38) | ANPEPLAP3 | |
| SCHEMBL12719694 | 0.71 | — | — | |
| SCHEMBL17533126 | 0.71 | — | — | |
| SCHEMBL16720986 | 0.69 | APLNR (0.38) | ANPEPLAP3 | |
| SCHEMBL15497542 | 0.67 | ANPEP (0.30) | ANPEPLAP3 | |
| Dioxane SCHEMBL25176962 | 0.67 | TTR (0.38) | ANPEPLAP3 | |
| SCHEMBL18056974 | 0.67 | ANPEP (0.32) | ANPEPLAP3 | |
| SCHEMBL19117714 | 0.65 | — | — | |
| SCHEMBL7067157 | 0.65 | ANPEP (0.31) | ANPEPLAP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230047396-A1 | INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2023-02-16 | — | — | US | disclosed |
| US-20230044112-A1 | HEPATITIS B CORE PROTEIN MODULATORS | ASSEMBLY BIOSCIENCES, INC. (US) | 2023-02-09 | — | — | US | disclosed |
| US-20230013144-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | TENARX, INC. | 2023-01-19 | — | — | US | disclosed |
| US-11066388-B2 | Indazole-3-carboxamides and their use as WNT/B-catenin signaling pathway inhibitors | BIOSPLICE THERAPEUTICS, INC. (US) | 2021-07-20 | — | — | US | disclosed |
| WO-2021072156-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2021-04-15 | — | — | WO | disclosed |
| US-10968211-B2 | Hepatitis B core protein modulators | ASSEMBLY BIOSCIENCES, INC. (US) | 2021-04-06 | — | — | US | disclosed |
| US-10947228-B2 | Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof | SAMUMED, LLC (US) | 2021-03-16 | — | — | US | disclosed |
| US-10806726-B2 | Methods of using indazole-3-carb oxamides and their use as Wnt/B-catenin signaling pathway inhibitors | SAMUMED, LLC (US) | 2020-10-20 | — | — | US | disclosed |
| US-20200239436-A1 | INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2020-07-30 | — | — | US | disclosed |
| US-10710978-B2 | STK4 inhibitors for treatment of hematologic malignancies | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-07-14 | — | — | US | disclosed |
| US-20180221351-A1 | 3-(1H-PYRROLO[2,3-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINES AND THERAPEUTIC USES THEREOF | MED-PATHWAYS II LIMITED (VG) | 2018-08-09 | — | — | US | disclosed |
| US-20180185343-A1 | METHODS OF USING INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2018-07-05 | — | — | US | disclosed |
| US-9994563-B2 | Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof | SAMUMED, LLC (US) | 2018-06-12 | — | — | US | disclosed |
| US-20180111916-A1 | STK4 INHIBITORS FOR TREATMENT OF HEMATOLOGIC MALIGNANCIES | FONDAZIONE CENTRO SAN RAFFAELE (IT) | 2018-04-26 | — | — | US | disclosed |
| US-9592235-B2 | Aminoquinazoline and pyridopyrimidine derivatives | GENENTECH, INC. (US) | 2017-03-14 | — | — | US | disclosed |
| WO-2014082379-A9 | SPIRO RING COMPOUND AS HEPATITIS C VIRUS (HCV) INHIBITOR AND USES THEREOF FIELD OF THE INVENTION | SUNSHINE LAKE PHARMA CO.,LTD. (CN) | 2016-02-25 | — | — | WO | disclosed |
| US-20150299125-A1 | PRODRUG BIPYRIDYLAMINOPYRIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-10-22 | — | — | US | disclosed |
| WO-2014082379-A1 | SPIRO RING COMPOUND AS HEPATITIS C VIRUS (HCV) INHIBITOR AND USES THEREOF FIELD OF THE INVENTION | SUNSHINE LAKE PHARMA CO.,LTD. (CN) | 2014-06-05 | — | — | WO | disclosed |
| EP-2657231-A2 | SUBSTITUTED AZOLES, ANTI-VIRAL ACTIVE INGREDIENT, PHARMACEUTICAL COMPOSITION, METHOD FOR THE PRODUCTION AND USE THEREOF | Ivachtchenko, Alexandre Vasilievich (US) | 2013-10-30 | — | — | EP | disclosed |
| EP-2246333-A1 | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors | Abbott Laboratories (US) | 2010-11-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10947228-B2 | Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof | WNT1, WNT3, WNT3A | ANPEP 3568/4885LAP3 3430/4885 |
| US-20230047396-A1 | INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS | WNT1, WNT3, WNT3A | ANPEP 3560/4885LAP3 3567/4885 |
| US-10806726-B2 | Methods of using indazole-3-carb oxamides and their use as Wnt/B-catenin signaling pathway inhibitors | CTNNB1, GSK3B, WNT3 | ANPEP 2961/4885LAP3 3673/4885 |
| US-20180185343-A1 | METHODS OF USING INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS | WNT3, CTNNB1, WNT3A | ANPEP 3479/4885LAP3 3227/4885 |
| US-20150299125-A1 | PRODRUG BIPYRIDYLAMINOPYRIDINES AS SYK INHIBITORS | SYK, IRAK1, BTK | ANPEP 2095/4885LAP3 1619/4885 |
| US-20230013144-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | ANPEP 3568/4885LAP3 3430/4885 |
| US-20230044112-A1 | HEPATITIS B CORE PROTEIN MODULATORS | HAVCR2, FABP1, MAVS | ANPEP 867/4885LAP3 1325/4885 |
| US-20200239436-A1 | INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS | WNT1, WNT3, WNT3A | ANPEP 3560/4885LAP3 3567/4885 |
| US-11066388-B2 | Indazole-3-carboxamides and their use as WNT/B-catenin signaling pathway inhibitors | WNT1, WNT3, WNT3A | ANPEP 3560/4885LAP3 3567/4885 |
| US-10968211-B2 | Hepatitis B core protein modulators | HAVCR2, FABP1, MAVS | ANPEP 867/4885LAP3 1325/4885 |
| US-20180111916-A1 | STK4 INHIBITORS FOR TREATMENT OF HEMATOLOGIC MALIGNANCIES | STK4, STK3, STK11 | ANPEP 4438/4885LAP3 4711/4885 |
| US-20180221351-A1 | 3-(1H-PYRROLO[2,3-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINES AND THERAPEUTIC USES THEREOF | WNT3, WNT1, WNT3A | ANPEP 3359/4885LAP3 3071/4885 |
| US-10710978-B2 | STK4 inhibitors for treatment of hematologic malignancies | STK4, STK3, STK11 | ANPEP 4438/4885LAP3 4711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.